Published in Sci Transl Med on April 03, 2013
The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe (2014) 7.43
The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology (2014) 2.73
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science (2015) 2.50
Using targeted chromatin regulators to engineer combinatorial and spatial transcriptional regulation. Cell (2014) 2.27
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell (2016) 2.15
Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell (2016) 1.82
A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice. Nat Commun (2013) 1.71
Extracellular vesicles from neural stem cells transfer IFN-γ via Ifngr1 to activate Stat1 signaling in target cells. Mol Cell (2014) 1.22
Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol (2016) 1.15
Synchronized cycles of bacterial lysis for in vivo delivery. Nature (2016) 1.05
Developing cellular therapies for retinal degenerative diseases. Invest Ophthalmol Vis Sci (2014) 1.03
Neural precursor cells in the ischemic brain - integration, cellular crosstalk, and consequences for stroke recovery. Front Cell Neurosci (2014) 0.98
Regulatory T cells and their roles in immune dysregulation and allergy. Immunol Res (2014) 0.94
Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation. Biomaterials (2014) 0.94
Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech (2014) 0.92
Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal. Proc Natl Acad Sci U S A (2014) 0.92
Synthetic biology to access and expand nature's chemical diversity. Nat Rev Microbiol (2016) 0.91
Toward beta cell replacement for diabetes. EMBO J (2015) 0.86
Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia (2014) 0.86
Synthetic mixed-signal computation in living cells. Nat Commun (2016) 0.86
It's time to bring dendritic cell therapy to type 1 diabetes. Diabetes (2014) 0.85
Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012. Am J Respir Crit Care Med (2013) 0.85
The Principles of Engineering Immune Cells to Treat Cancer. Cell (2017) 0.85
Near-infrared light responsive synthetic c-di-GMP module for optogenetic applications. ACS Synth Biol (2014) 0.84
Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol (2015) 0.84
Immune Tolerance for Autoimmune Disease and Cell Transplantation. Annu Rev Biomed Eng (2016) 0.83
Nanoparticles and clinically applicable cell tracking. Br J Radiol (2015) 0.83
Cyclooxygenase-2 or tumor necrosis factor-α inhibitors attenuate the mechanotransductive effects of pulsed focused ultrasound to suppress mesenchymal stromal cell homing to healthy and dystrophic muscle. Stem Cells (2015) 0.82
Amnion cell-mediated immune modulation following bleomycin challenge: controlling the regulatory T cell response. Stem Cell Res Ther (2015) 0.81
Synthetic microbes as drug delivery systems. ACS Synth Biol (2014) 0.81
Beyond traditional pharmacology: new tools and approaches. Br J Pharmacol (2015) 0.80
Reward-based hypertension control by a synthetic brain-dopamine interface. Proc Natl Acad Sci U S A (2013) 0.80
Mesenchymal stromal cells in the development and therapy of bronchopulmonary dysplasia. Mol Cell Pediatr (2016) 0.80
Therapeutic Strategies for Oxidative Stress-Related Cardiovascular Diseases: Removal of Excess Reactive Oxygen Species in Adult Stem Cells. Oxid Med Cell Longev (2016) 0.80
Systematic transfer of prokaryotic sensors and circuits to mammalian cells. ACS Synth Biol (2014) 0.79
Imaging transplanted stem cells in real time using an MRI dual-contrast method. Sci Rep (2015) 0.79
The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. Prog Neurobiol (2015) 0.79
Synthetic biology approaches to engineer T cells. Curr Opin Immunol (2015) 0.78
Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway. Cell Mol Immunol (2016) 0.78
Spatial and functional heterogeneities shape collective behavior of tumor-immune networks. PLoS Comput Biol (2015) 0.77
Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies. Oncoimmunology (2014) 0.77
NF-κB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment. Oncotarget (2015) 0.77
Stem Cells and Their Mediators - Next Generation Therapy for Bronchopulmonary Dysplasia. Front Med (Lausanne) (2015) 0.77
Photothermal enhancement of chemotherapy mediated by gold-silica nanoshell-loaded macrophages: in vitro squamous cell carcinoma study. J Biomed Opt (2016) 0.77
Rewiring the ischaemic brain with human-induced pluripotent stem cell-derived cortical neurons. Brain (2013) 0.76
Protein engineering: a new frontier for biological therapeutics. Curr Drug Metab (2014) 0.76
Challenges in the translation and commercialization of cell therapies. BMC Biotechnol (2015) 0.76
Towards the computational design of protein post-translational regulation. Bioorg Med Chem (2015) 0.76
A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes. Mol Ther (2017) 0.75
The nanomaterial toolkit for neuroengineering. Nano Converg (2016) 0.75
PDGFB-based stem cell gene therapy increases bone strength in the mouse. Proc Natl Acad Sci U S A (2015) 0.75
Cell Mediated Photothermal Therapy of Brain Tumors. J Neuroimmune Pharmacol (2016) 0.75
Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson's Disease. Yale J Biol Med (2016) 0.75
A Synthetic Mammalian Therapeutic Gene Circuit for Sensing and Suppressing Inflammation. Mol Ther (2017) 0.75
Facilitating cells: Translation of hematopoietic chimerism to achieve clinical tolerance. Chimerism (2016) 0.75
Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy. Exp Ther Med (2016) 0.75
Adipose-Derived Mesenchymal Stem Cells Ameliorate Lipid Metabolic Disturbance in Mice. Stem Cells Transl Med (2016) 0.75
The site of allergen expression in hematopoietic cells determines the degree and quality of tolerance induced through molecular chimerism. Eur J Immunol (2013) 0.75
Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. Annu Rev Pathol (2016) 0.75
Engineered Swine Models of Cancer. Front Genet (2016) 0.75
Polymer-DNA Nanoparticle-Induced CXCR4 Overexpression Improves Stem Cell Engraftment and Tissue Regeneration in a Mouse Hindlimb Ischemia Model. Theranostics (2016) 0.75
Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy. EBioMedicine (2016) 0.75
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities. Annu Rev Immunol (2017) 0.75
Targeted Cell-to-Cell Delivery of Protein Payloads via the Granzyme-Perforin Pathway. Mol Ther Methods Clin Dev (2017) 0.75
The modulation of enzyme indoleamine 2,3-dioxygenase from dendritic cells for the treatment of type 1 diabetes mellitus. Drug Des Devel Ther (2017) 0.75
Empirical Modeling of T cell Activation Predicts Interplay of Host Cytokines and Bacterial Indole. Biotechnol Bioeng (2017) 0.75
Antioxidant Therapeutic Strategies for Cardiovascular Conditions Associated with Oxidative Stress. Nutrients (2017) 0.75
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med (2013) 20.65
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science (2000) 10.81
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2003) 8.59
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
T cell anergy. Annu Rev Immunol (2001) 7.15
Spatiotemporal control of cell signalling using a light-switchable protein interaction. Nature (2009) 6.74
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2010) 5.79
Synthetic gene networks that count. Science (2009) 4.54
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome (2013) 3.56
Designing customized cell signalling circuits. Nat Rev Mol Cell Biol (2010) 2.64
Human neural stem cells induce functional myelination in mice with severe dysmyelination. Sci Transl Med (2012) 1.82
Microbiota-targeted therapies: an ecological perspective. Sci Transl Med (2012) 1.80
Therapeutic modulation of microbiota-host metabolic interactions. Sci Transl Med (2012) 1.45
Cell therapy industry: billion dollar global business with unlimited potential. Regen Med (2011) 1.29
Community health care: therapeutic opportunities in the human microbiome. Sci Transl Med (2011) 1.14
FDA oversight of cell therapy clinical trials. Sci Transl Med (2012) 1.12
Pluripotent stem cell-based cancer therapy: promise and challenges. Sci Transl Med (2012) 0.99
A decade of cell therapy clinical trials (2000-2010). Regen Med (2012) 0.97
Stem cell therapies could change medicine... if they get the chance. Cell Stem Cell (2012) 0.96
Advancing stem cell biology toward stem cell therapeutics. Cell Stem Cell (2012) 0.90
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell (2013) 13.43
Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature (2008) 12.45
CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell (2013) 9.55
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44
Spatiotemporal control of cell signalling using a light-switchable protein interaction. Nature (2009) 6.74
The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 6.71
The genome of the choanoflagellate Monosiga brevicollis and the origin of metazoans. Nature (2008) 6.69
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
Defining network topologies that can achieve biochemical adaptation. Cell (2009) 5.49
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20
Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature (2007) 4.94
Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med (2008) 4.68
TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 4.40
Using engineered scaffold interactions to reshape MAP kinase pathway signaling dynamics. Science (2008) 4.37
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Scaffold proteins: hubs for controlling the flow of cellular information. Science (2011) 4.00
Rewiring MAP kinase pathways using alternative scaffold assembly mechanisms. Science (2003) 3.90
Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol (2003) 3.86
Optimization of specificity in a cellular protein interaction network by negative selection. Nature (2003) 3.71
Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med (2005) 3.70
The Ste5 scaffold allosterically modulates signaling output of the yeast mating pathway. Science (2006) 3.64
Domains, motifs, and scaffolds: the role of modular interactions in the evolution and wiring of cell signaling circuits. Annu Rev Biochem (2006) 3.60
Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med (2012) 3.40
Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol (2004) 3.18
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
Reprogramming control of an allosteric signaling switch through modular recombination. Science (2003) 3.15
A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity (2005) 3.07
CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
Deciphering protein kinase specificity through large-scale analysis of yeast phosphorylation site motifs. Sci Signal (2010) 2.95
Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol (2009) 2.93
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86
NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity (2004) 2.80
A polybasic motif allows N-WASP to act as a sensor of PIP(2) density. Mol Cell (2005) 2.80
Systematic functional prioritization of protein posttranslational modifications. Cell (2012) 2.78
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Evolution of phosphoregulation: comparison of phosphorylation patterns across yeast species. PLoS Biol (2009) 2.67
Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity (2003) 2.57
Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant (2004) 2.55
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52
The Ste5 scaffold directs mating signaling by catalytically unlocking the Fus3 MAP kinase for activation. Cell (2009) 2.50
Rapid diversification of cell signaling phenotypes by modular domain recombination. Science (2010) 2.49
Rewiring cellular morphology pathways with synthetic guanine nucleotide exchange factors. Nature (2007) 2.43
Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity (2013) 2.41
Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol (2011) 2.39
Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology (2007) 2.33
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30
Positive selection of tyrosine loss in metazoan evolution. Science (2009) 2.28
Designing synthetic regulatory networks capable of self-organizing cell polarization. Cell (2012) 2.28
The structure and function of proline recognition domains. Sci STKE (2003) 2.25
Using optogenetics to interrogate the dynamic control of signal transmission by the Ras/Erk module. Cell (2013) 2.22
Scaffolds: interaction platforms for cellular signalling circuits. Trends Cell Biol (2009) 2.15
Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 2.13
Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev (2006) 2.13
CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med (2008) 2.07
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06
CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nat Protoc (2013) 2.05
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00
Docking interactions in protein kinase and phosphatase networks. Curr Opin Struct Biol (2006) 2.00
Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest (2003) 1.95
The role of docking interactions in mediating signaling input, output, and discrimination in the yeast MAPK network. Mol Cell (2005) 1.94
Conformational control of the Ste5 scaffold protein insulates against MAP kinase misactivation. Science (2012) 1.92
Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 1.90
The promise of optogenetics in cell biology: interrogating molecular circuits in space and time. Nat Methods (2010) 1.87
Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet (2003) 1.85
Rewiring cell signaling: the logic and plasticity of eukaryotic protein circuitry. Curr Opin Struct Biol (2004) 1.83
Secreting and sensing the same molecule allows cells to achieve versatile social behaviors. Science (2014) 1.80
Light-based feedback for controlling intracellular signaling dynamics. Nat Methods (2011) 1.79
Rewiring cells: synthetic biology as a tool to interrogate the organizational principles of living systems. Annu Rev Biophys (2010) 1.78
Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol (2006) 1.75
Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest (2004) 1.74
How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes (2011) 1.74
Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol (2005) 1.73
Bacterial virulence proteins as tools to rewire kinase pathways in yeast and immune cells. Nature (2012) 1.73
Structure of the N-WASP EVH1 domain-WIP complex: insight into the molecular basis of Wiskott-Aldrich Syndrome. Cell (2002) 1.70
Murine pancreatic islet isolation. J Vis Exp (2007) 1.68
Evolution of the phospho-tyrosine signaling machinery in premetazoan lineages. Proc Natl Acad Sci U S A (2008) 1.68
Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes (2007) 1.67
Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol (2005) 1.67
A resource for the conditional ablation of microRNAs in the mouse. Cell Rep (2012) 1.66
Engineering synthetic signaling proteins with ultrasensitive input/output control. Nat Biotechnol (2007) 1.66
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest (2010) 1.63
Notch 1 signaling regulates peripheral T cell activation. Immunity (2004) 1.61
Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Semin Immunol (2006) 1.55
IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A (2012) 1.54
The microRNA cluster miR-17∼92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol (2013) 1.50
Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes (2006) 1.49
Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol (2011) 1.49
The pathogen protein EspF(U) hijacks actin polymerization using mimicry and multivalency. Nature (2008) 1.48